|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004587,
umls-concept:C0005684,
umls-concept:C0014582,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0442124,
umls-concept:C1282910,
umls-concept:C1306673,
umls-concept:C2603343
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-2-24
|
|
pubmed:abstractText |
Bacillus Calmette-Guérin (BCG) instillation is regarded as the most effective bladder-sparing treatment for patients with high-grade T1 tumours and carcinoma in situ (CIS). The major problem with this therapy is the side-effects, making maintenance therapy difficult, even impossible, in a proportion of patients. Thus, alternative schedules and drugs have been proposed.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1873-7560
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19819617-Administration, Intravesical,
pubmed-meshheading:19819617-Aged,
pubmed-meshheading:19819617-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19819617-BCG Vaccine,
pubmed-meshheading:19819617-Carcinoma,
pubmed-meshheading:19819617-Chemotherapy, Adjuvant,
pubmed-meshheading:19819617-Cystectomy,
pubmed-meshheading:19819617-Disease Progression,
pubmed-meshheading:19819617-Disease-Free Survival,
pubmed-meshheading:19819617-Epirubicin,
pubmed-meshheading:19819617-Female,
pubmed-meshheading:19819617-Humans,
pubmed-meshheading:19819617-Interferon-alpha,
pubmed-meshheading:19819617-Kaplan-Meier Estimate,
pubmed-meshheading:19819617-Male,
pubmed-meshheading:19819617-Neoplasm Recurrence, Local,
pubmed-meshheading:19819617-Neoplasm Staging,
pubmed-meshheading:19819617-Proportional Hazards Models,
pubmed-meshheading:19819617-Prospective Studies,
pubmed-meshheading:19819617-Recombinant Proteins,
pubmed-meshheading:19819617-Risk Assessment,
pubmed-meshheading:19819617-Risk Factors,
pubmed-meshheading:19819617-Scandinavia,
pubmed-meshheading:19819617-Time Factors,
pubmed-meshheading:19819617-Treatment Outcome,
pubmed-meshheading:19819617-Tumor Burden,
pubmed-meshheading:19819617-Urinary Bladder Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
|
|
pubmed:affiliation |
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
